{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:55:34Z","timestamp":1791111334617,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1124\/dmd.110.033407","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T04:24:15Z","timestamp":1275971055000},"page":"1456-1463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics"],"prefix":"10.1016","volume":"38","author":[{"given":"Masayo","family":"Oishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.110.033407_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","article-title":"Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications","volume":"11","author":"Bernard","year":"2006","journal-title":"Oncologist"},{"key":"10.1124\/dmd.110.033407_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.110.033407_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0009-9236(98)90104-7","article-title":"Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine","volume":"63","author":"Brynne","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.033407_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002512-200118040-00005","article-title":"Tolterodine: a review of its use in the treatment of overactive bladder","volume":"18","author":"Clemett","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1124\/dmd.110.033407_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.110.033407_bib6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1023\/B:PHAM.0000026429.12114.7d","article-title":"Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes","volume":"21","author":"Ito","year":"2004","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.110.033407_bib7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0026-895X(25)09721-4","article-title":"Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation","volume":"46","author":"Johansson","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.110.033407_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2133\/dmpk.18.365","article-title":"The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature","volume":"18","author":"Kato","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.110.033407_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":"Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.110.033407_bib10","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0090-4295(98)00629-3","article-title":"Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data","volume":"53","author":"Larsson","year":"1999","journal-title":"Urology"},{"key":"10.1124\/dmd.110.033407_bib11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.5414\/CPP46556","article-title":"Pharmacokinetic profile of fesoterodine","volume":"46","author":"Malhotra","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.033407_bib12","first-page":"13","article-title":"The mechanism of action of tolterodine","volume":"11","author":"Nilvebrant","year":"2000","journal-title":"Rev Contemp Pharmacother"},{"key":"10.1124\/dmd.110.033407_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","article-title":"Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine","volume":"40","author":"Olsson","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.110.033407_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","article-title":"Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1","volume":"19","author":"Ozawa","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.110.033407_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y","article-title":"Serum protein binding of tolterodine and its major metabolites in humans and several animal species","volume":"20","author":"P\u00e5hlman","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.110.033407_bib16","first-page":"289","article-title":"Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes","volume":"26","author":"Postlind","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.033407_bib17","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1124\/dmd.108.023242","article-title":"Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47\u201351, 53\u201355, and 57)","volume":"36","author":"Sakuyama","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.033407_bib18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.107.015354","article-title":"Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17","volume":"35","author":"Shen","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.033407_bib19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1124\/dmd.110.033407_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2133\/dmpk.18.269","article-title":"Two novel haplotypes of CYP2D6 gene in a Japanese population","volume":"18","author":"Yamazaki","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.110.033407_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00008571-199310000-00005","article-title":"Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism","volume":"3","author":"Yokota","year":"1993","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.110.033407_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.110.033407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:51:12Z","timestamp":1739897472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624024565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0090955624024565"],"URL":"https:\/\/doi.org\/10.1124\/dmd.110.033407","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.110.033407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}